Xenon Seven

Xenon Seven

Director/Senior Director, Forecast & Research

Boston · Director

Sponsorship not specifiedDetected 84 days ago
RESTBusiness DevelopmentForecastingVendor ManagementClinical TrialsResearchLeadershipCommunicationCollaborationEpidemiology

About the role

  • We are seeking a Director/Senior Director, Forecast & Research to join our growing Commercial organization.
  • This position reports to the Vice, President, Commercial Operations and will be based out of Boston, MA, USA in our Needham office.
  • Remote locations will be considered for exceptional candidates.

Responsibilities

  • Lead the development, maintenance, and evolution of patient‑based and revenue‑based forecasts for Xenon's assets.
  • Partner closely with functional leaders to align on key assumptions, scenario planning, sensitivity analyses, and long‑range forecasting inputs.
  • Collaborate with cross-functional colleagues to ensure forecasting accuracy for operational planning.
  • Develop and present forecast updates to senior leadership, ensuring cross‑functional alignment and transparency.
  • Design and execute primary market research, including vendor selection, methodology design, and synthesis of insights across HCPs, payers, patients, and caregivers.
  • Provide analytical and insights support for business development assessments as needed.
  • Manage external vendors/agencies to ensure high‑quality deliverables, budget adherence, and methodological rigor.
  • Develop and propose short‑ and long‑term objectives for the function in accordance with overall Company strategies and plans.
  • Plan and manage budget proposals and approved budgets in alignment with Company policies.

Requirements

  • Minimum undergraduate degree.
  • 10+ years of relevant management experience or combination of degrees and experience.
  • Demonstrated expertise in forecasting methodologies and scenario planning.
  • Track record of translating complex data into strategic recommendations for senior leadership.
  • Vendor management experience required.
  • Ability to thrive in a dynamic, fast‑paced, growth‑stage environment
  • Some international travel may be required.
  • Minimum undergraduate degree. 10+ years of relevant management experience or combination of degrees and experience.
  • Excellent communication, collaboration, and cross‑functional influencing skills.
  • Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance programs, Employee Assistance Program, travel insurance, and retirement savings programs with company matching contributions.
  • Xenon encourages time to rest and re-charge through vacation, personal days, sick days, and an end-of-year company shutdown. Xenon highly values employee development and has an expanding Training, Learning & Development program, including a Tuition Assistance program for advanced degrees.

Nice to have

  • Experience in neurology strongly preferred
  • epilepsy experience highly desirable.

Compensation

  • Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance progr

Company info

  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • What We Do:
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
  • We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain.
  • Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
  • In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.
  • Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication.
  • We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.
  • In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting.
  • We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets.
  • Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
Apply directly at Xenon Seven →Create a free account for alerts like thisView Xenon Seven immigration profile

This listing is sourced directly from Xenon Seven's careers page and normalized into a canonical job model.